BL
BMRN icon

BFSG LLC’s BioMarin Pharmaceuticals BMRN Stock Holding History

BFSG LLC’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-6,606
Closed -$815K – 185
2020
Q2 		$815K Sell
6,606
-558
-8% -$55.5K 0.18% 97
2020
Q1 		$605K Sell
7,164
-91
-1% -$7.84K 0.16% 107
2019
Q4 		$613K Buy
+7,255
New +$548K 0.12% 141

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BFSG LLC's BMRN Position: Q3 2020 in Review

BFSG LLC sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2020, closing a stake of 6,606 shares — an estimated $815K sold.

BFSG LLC first reported a position in BMRN in Q4 2019 and held it in 3 quarters. The position peaked at $815K in Q2 2020. 496 funds tracked by Wall St. Rank hold BMRN as of Q3 2020.

  • BFSG LLC reported no remaining BioMarin Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • BFSG LLC sold 6,606 BioMarin Pharmaceuticals shares in Q3 2020, an estimated $815K.
  • BFSG LLC first reported a position in BioMarin Pharmaceuticals in Q4 2019 and held it in 3 quarters.
  • BFSG LLC's BioMarin Pharmaceuticals position peaked at $815K in Q2 2020.
  • 496 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2020.

Based on BFSG LLC's 13F filing for Q3 2020, filed 4 Nov 2020.